Editas Medicine (EDIT) Interest Expenses (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Interest Expenses data on file, last reported at $1.4 million in Q4 2025.

• On a quarterly basis, Interest Expenses fell 89.07% year-over-year to $1.4 million in Q4 2025; TTM through Dec 2025 was $1.4 million, a 91.6% decrease from a year earlier, with the FY2025 full-year figure at $1.4 million, down 92.44% from the prior year.
• Interest Expenses for Q4 2025 stood at $1.4 million, down from $7.6 million in the prior quarter.
• Over the last five years, Interest Expenses for EDIT reached as high as $4.0 billion in Q1 2022 and fell as low as -$7.7 million in Q4 2021.
• Historically, Interest Expenses has averaged $417.1 million across 5 years, with a median of $20.6 million in 2021.
• Across the five-year window, Interest Expenses plunged 485.32% in 2021 and soared 9023.09% in 2022, its largest moves.
• Year by year, Interest Expenses stood at -$7.7 million in 2021, then surged by 62.83% to -$2.9 million in 2022, then soared by 154.51% to $1.6 million in 2023, then jumped by 716.37% to $12.8 million in 2024, then sank by 89.07% to $1.4 million in 2025.
• Per Business Quant data, the three most recent Interest Expenses figures were $1.4 million in Q4 2025, $7.6 million in Q3 2025, and $2.5 million in Q2 2025.